BioCentury | Oct 17, 2020
Translation in Brief

SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more

...death 1 Danielle Golovin PBGM01 Veklury, remdesivir (GS-5734) Viracept, nelfinavir (ARV-SR0121, AG-1343) Tybost...
BioCentury | Mar 24, 2016
Distillery Therapeutics

Therapeutics: BRAF; MEK; neuroblastoma Ras viral (v-Ras) oncogene (NRAS)

...Cancer INDICATION: Melanoma Cell culture and mouse studies suggest Viracept nelfinavir could help treat melanoma that...
...melanoma cell line, Viracept increased sensitivity to selumetinib. In a xenograft mouse model of melanoma, Viracept...
...model of NRAS-mutant melanoma, Viracept plus selumetinib decreased tumor growth. Next steps could include testing Viracept...
BioCentury | Jun 21, 2010
Strategy

Playing Brazil

...is best remembered for threatening the compulsory licensing of the patent covering HIV drug Viracept nelfinavir...
BioCentury | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

...found that Pfizer Inc. 's HIV protease inhibitor Viracept nelfinavir had anti-HCV activity. "But if nelfinavir...
...patient who was unknowingly co-infected with HIV, then there would be a high likelihood for nelfinavir-resistant...
...system inhaler to treat migraine; available as a generic to treat nausea and vertigo Viracept nelfinavir...
BioCentury | Jul 21, 2008
Company News

Roche infectious news

...decision does not affect Roche’s marketed HIV drugs, including Fuzeon enfuvirtide, Invirase saquinavir, and Viracept nelfinavir...
...is licensed from Trimeris Inc. (NASDAQ:TRMS, Morrisville, N.C.). Invirase and Viracept are HIV protease inhibitors. Viracept...
BioCentury | Jun 12, 2008
Distillery Therapeutics

This Week in Therapeutics

...treating RD and other neurodegenerative ophthalmic conditions. In cultured primary retinal cells, the protease inhibitor nelfinavir...
...with what was seen in untreated controls. In mice, a combination of two protease inhibitors, nelfinavir...
...injury, Parkinson's disease (PD) and Alzheimer's disease (AD). Pfizer Inc. and Abbott Laboratories market Viracept nelfinavir...
BioCentury | Jun 12, 2008
Targets & Mechanisms

Eyeing New Uses for Protease Inhibitors

...been shown to induce apoptosis by inhibiting the phosphorylation of protein kinase B (Akt). 7,8 Nelfinavir...
...mitochondrial targets of the protease inhibitors. Abbott Laboratories markets Norvir ritonavir. Pfizer Inc. markets Viracept nelfinavir...
...Reyataz atazanavir Johnson & Johnson (NYSE:JNJ) Prezista darunavir Merck Crixivan indinavir Pfizer Inc. (NYSE:PFE) Viracept nelfinavir...
BioCentury | Sep 24, 2007
Strategy

Ship, captain and crew

...on the senior team at Agouron Pharmaceuticals Inc. , which developed the protease inhibitor Viracept nelfinavir...
BioCentury | Sep 24, 2007
Clinical News

Viracept nelfinavir regulatory update

...EMEA's CHMP recommended reinstating an MAA for ROG's Viracept nelfinavir to treat HIV infection. The application...
...issued a "Dear Healthcare Professional" letter earlier this month to provide guidance on use of Viracept...
...BioCentury, Sept. 17). Pfizer Inc. (PFE), New York, N.Y. Roche (SWX:ROG), Basel, Switzerland Product: Viracept nelfinavir...
BioCentury | Sep 17, 2007
Clinical News

Viracept nelfinavir regulatory update

...the presence of ethyl methanesulfonate (EMS), a process-related impurity and potential human carcinogen, in Viracept nelfinavir...
...ratio remains favorable and the patients may continue to receive Viracept. However, pregnant women on Viracept...
...to begin HIV treatment should not start regimens containing Viracept until further notice. PFE markets Viracept...
Items per page:
1 - 10 of 179